MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
The New York Genome Center (NYGC) has received approval from the New York State Department of Health to offer whole genome and RNA transcriptome sequencing in its Clinical Laboratory Evaluation ...
Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey We validated a clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback